This is a preview of subscription content, log in via an institution to check access.
References
Reference
US FDA. FDA creates web page with drug safety information for patients, health care professionals. Media release: 15 Oct 2008. Available from URL: http://www.fda.gov
References
Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008 Oct 22; 300 (16): 1887–96
DeAngelis CD, Fontanarosa PB. Prescription drugs, products liability, and preemption of tort litigation. JAMA 2008 Oct 22; 300 (16): 1939–41
Reference
Goodyear MDE, Eckenwiler LA, Ells C. Fresh thinking about the Declaration of Helsinki: a comprehensive approach to ethical research. BMJ 2008 Nov 8; 337 (7678): 1067–8
Reference
The UK panel of research integrity: a missed opportunity. Lancet 2008 Oct 25; 372(9648): 1438
Reference
Choudhry NK, Cox E, Fischer MA, et al. Setting prices for generic medications: a survey of patients perceptions [abstract 237]. 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2008 Aug 17–20; Copenhagen
References
Graf von der Schulenburg J-M, Greiner W, Jost F, et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008 Jul–Aug; 11 (4): 539–44
Kolominsky-Rabas PL, Caro JJ. The Hanover Consensus: helpful for German decision-makers? Value Health 2008 Jul–Aug; 11 (4): 545–6
Graf von der Schulenburg J-M, Mittendorf T, Vauth C, et al. Scientific guidelines and their implementation in health policy. Value Health 2008 Jul–Aug; 11 (4): 547–8
Reference
Rocchi A, Menon D, Verma S, et al. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health 2008 Jul–Aug; 11 (4): 771–83
Reference
Blum J. Woodcock gain support from drugmakers for U.S. FDA’s top job. 2008 Nov 7 [online]. Available from URL: http://www.bloomberg.com [Accessed 2008 Dec 3]
Reference
Berger E. Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research. Ann Emerg Med 2008 Aug; 52 (2): 137–9
Reference
de Ferranti S, Ludwig DS. Storm over statins: the controversy surrounding pharmacologic treatment of children. N Engl J Med 2008 Sep 25; 359 (13): 1309–12
Reference
Heng HHQ. The conflict between complex systems and reductionism. JAMA 2008 Oct 1; 300 (13): 1580–1
Reference
Grobler L, Siegried N, Askie L, et al. National and multinational prospective trial registers. Lancet 2008 Oct 4; 372 (9645): 1201–2
Reference
Breckenridge A, Hudson I. How European regulators view foreign data in the approval process. Clin Pharmacol Ther 2008 Sep; 84 (3): 311–2
Reference
Lean MEJ, Mann JI, Hoek JA, et al. Translation research: from evidence based medicine to sustainable solutions for public health problems. BMJ 2008 Sep 27; 337 (7672): 704–5
Reference
Hampton T. Academic medical centers embark on public outreach through the internet. JAMA 2008 Sep 3; 300 (9): 1015
Reference
Lenzer J. Truly independent research? BMJ 2008 Sep 13; 337 (7670): 602–6
Reference
RCTs on undeserved pedestal, says Rawlins. Pharm J 2008 Oct 25; 281 (7525): 434
Reference
Genzyme Corporation. Genzyme and the International Center for Genetic Engineering and Biotechnology form collaboration to advance treatments for neglected diseases. Media release: 18 Nov 2008 [online]. Available from URL: http://www.genzyme.com
Rights and permissions
About this article
Cite this article
Forum. Pharm Med 22, 381–388 (2008). https://doi.org/10.1007/BF03256736
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256736